Age

Any age

Sex

FEMALE

Healthy volunteers

Accepted

1. Female, ≥18 years, Egyptian nationality.
2. Breast cancer (any stage) with planned anthracycline containing chemotherapy (intended cumulative DOX ≥240 mg/m² or epirubicin ≥360 mg/m² equivalents).
3. Baseline echo suitable for LVEF ≥53%.
4. Able to consent and comply with follow up.

• Type 1 and type 2 diabetes; history of diabetic ketoacidosis; pregnancy/lactation.
* Symptomatic HF, cardiomyopathy, significant valvular disease, prior anthracycline exposure.
* Baseline hypotension (SBP \<95 mmHg), recurrent UTIs/mycotic infections, active foot ulcer/critical limb ischemia.
* Inflammatory diseases, liver and kidney diseases.
* Autoimmune diseases.
* Other type of malignancies or metastatic diseases.
* Patients who exposed to surgery less than one month.
* Concomitant dexrazoxane planned upfront (allowed only for rescue; documented).
* Known hypersensitivity to study drugs.

Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC